Patents by Inventor Louis Cartilier

Louis Cartilier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100113619
    Abstract: A process for obtaining a spray-dried high amylose sodium carboxymethyl starch comprising a major fraction of amorphous form and optionally a minor fraction of crystalline V form, is provided. The process comprises providing an amorphous pregelatinized high amylose sodium carboxymethyl starch (HASCA); dispersing the amorphous pregelatinized HASCA in a solution comprising water and at least one first pharmaceutically acceptable organic solvent miscible with water and suitable for spray-drying; and spray-drying the dispersion to obtain the spray-dried HASCA comprising a major fraction of amorphous form and optionally a minor fraction of crystalline V form, in the form of a powder. Also provided is a spray-dried HASCA sustained-release excipient. This excipient is useful for preparing a tablet for the sustained-release of at least one drug.
    Type: Application
    Filed: June 5, 2008
    Publication date: May 6, 2010
    Applicant: UNIVERSITÉ DE MONTRÉAL
    Inventors: Fabien Brouillet, Bernard Bataille, Gilles Baylac, Louis Cartilier
  • Publication number: 20090011014
    Abstract: Disclosed is a pharmaceutical sustained release tablet for oral administration of a drug which is made of a compressed blend of at least three dry powders including a powder of a drug, a powder of a sustained release matrix for the drug, and a powder of at least one electrolyte. The sustained release matrix consisting of an un-cross-linked high amylose starch wherein the high amylose is substituted by at least one organic substituent comprising at least one carboxyl group. This organic substituent is preferably a carboxyalkyl having 2 to 4 carbon atoms, its salt or mixture thereof. This tablet has the advantage of having an improved integrity.
    Type: Application
    Filed: December 20, 2005
    Publication date: January 8, 2009
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Louis Cartilier, Mihaela Ungur, Chafic Chebli
  • Patent number: 5989589
    Abstract: Cross-linked cellulose is an excellent binder disintegrant that can be used in the preparation of pharmaceutical tablets. The tablets that are so prepared are made of a compressed mixture of a powder of a pharmaceutically active ingredient with a powder of a pharmaceutical excipient including a pharmaceutically acceptable form of cross-linked cellulose in an amount up to 35% by weight with respect to the total weight of the tablet. The cross-linked cellulose is prepared by cross-linking microcrystalline or fibrous cellulose with a cross-linking agent such as epichlorhydrin in a relative amount of 2 to 50 g of cross-linking agent per 100 g of cellulose. Tests have proved that cross-linked cellulose is very easy to synthetise and has excellent binding/disintegrating properties that are function of the cross-linking degree. At low cross-linking degree, cross-linked cellulose is more a binder than a disintegrant whereas at high cross-linking degree, it is more a disintegrant than a binder.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: November 23, 1999
    Inventors: Louis Cartilier, Chafic Chebli
  • Patent number: 5879707
    Abstract: A pharmaceutical sustained release tablet for oral administration is made of a compressed blend of at least two dry powders including a powder of a pharmaceutical drug and a powder of a sustained release matrix for the drug. The sustained release matrix is made of substituted amylose prepared by reacting, in a basic medium, amylose with an organic substituent having a reactive function that reacts with the hydroxy groups of the amylose molecule. This substituent is preferably an epoxy or halogen alkane or alcohol with such a matrix controlled and sustained release of a drug are achieved with a remarkable close-to-linear profile and a release time of from 9 to 20 hours.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: March 9, 1999
    Assignee: Universite De Montreal
    Inventors: Louis Cartilier, Iskandar Moussa, Chafic Chebli, Stephane Buczkowski
  • Patent number: 5616343
    Abstract: The present invention is concerned with the manufacture of solid dosage units (pharmaceutical and others). More specifically, the invention is related to powders of cross-linked amylose, having a specific cross-linking degree for use as tablet binders and disintegrants.
    Type: Grant
    Filed: March 25, 1993
    Date of Patent: April 1, 1997
    Assignee: Labopharm, Inc.
    Inventors: Louis Cartilier, Mircea A. Mateescu, Yves Dumoulin, Vincent Lenaerts
  • Patent number: 5603956
    Abstract: The present application is concerned with a solid slow release pharmaceutical dosage unit. More specifically, the invention is directed to a tablet form prepared by direct compression of cross-linked amylose (CLA) having a definite cross-linking degree, .alpha.-amylase and a pharmaceutical agent. The presence of the cross-linked amylose allows a sustained release of the drug, while the .alpha.-amylase permits the modulation of the release time. In other words, the release time of the drug is function of the amount of .alpha.-amylase in the tablet. The amount of .alpha.-amylase is defined in terms of Enzyme Units.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: February 18, 1997
    Assignee: Labopharm Inc.
    Inventors: Mircea A. Mateescu, Yves Dumoulin, Louis Cartilier, Vincent Lenaerts